Targeting the tumor vasculature: A strategy to improve radiation therapy

Expert Review of Anticancer Therapy

Volumn 4, Issue 2, 2004, Pages 321-327

  Siemann, Dietmar W ^a   Horsman, Michael R ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Angiogenesis; Radiotherapy; Tumor vasculature; Vascular targeting strategies

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ARSENIC TRIOXIDE; COMBRETASTATIN A4 PHOSPHATE; ENDOSTATIN; ENDOTHELIAL CELL GROWTH FACTOR; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; MITOFLAXONE; N ACETYLCOLCHINOL PHOSPHATE; PRODRUG; PROTEIN ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SUNITINIB; THROMBOSPONDIN; TIRAPAZAMINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR TARGETING AGENT; VATALANIB;

ANGIOGENESIS; BLOOD VESSEL INJURY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; CLINICAL STUDY; CLINICAL TRIAL; DRUG TARGETING; DRUG USE; ENDOTHELIUM INJURY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUTRITIONAL SUPPORT; REVIEW; TREATMENT PLANNING; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 1842689545     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.2.321     Document Type: Review

References (69)

1. Ausprunk D, Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc. Res. 14, 53-65 (1977).
2. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res. 46, 467-473 (1986).
3. Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L. Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response and postvascular dormancy. Cancer Res. 59, 4770-4775 (1999).
4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1, 27-31 (1995).
5. Tannock IF. Population kinetics of carcinoma cells, capillary endothelial cells and fibroblasts in a transplanted mouse mammary tumor. Cancer Res. 30, 2470-2477 (1970).
6. Vaupel P, Thews O, Hoeckel M. Tumor oxygenation: characterization and clinical implications. In: Erythropoietin in Cancer Supportive Treatment. Smyth JF, Boogaerts MA, Ehmer BR (Eds), Marcel Dekker Inc., NY, USA, 205-239 (1996).
7. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother Oncol. 53, 113-117 (1999).
8. 2 predicts survival in advanced cancer of the uterine cervix. Radiother. Oncol. 26, 45-50 (1993).
9. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinioma of the head and neck. Radiother. Oncol. 41, 31-39 (1996).
10. Durand RE. Keynote address: The influence of microenvironmental factors on the activity of radiation and drugs. Int. J. Radiat. Oncol. Biol. Phys. 20, 253-258 (1991).
11. Giaccia AJ. Hypoxic stress proteins: Survival of the fittest. Semin. Radiat. Oncol. 6, 46-58 (1996).
12. De Jaeger K, Kavanagh MC, Hill RP. Relationship of hypoxia to metastatic ability in rodent tumours. Br. J. Cancer 84, 1280-1285 (2001).
13. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103, 159-165 (1999).
14. Gorski DH, Beckett MA, Jaskowiak NT et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59, 3374-3378 (1999).
15. Wedge SR, Ogilvie DJ, Dukes M et al. ZD4190: An orally-active inhibitor of vascular endothelial growth factor signaling with broad spectrum antitumor efficacy. Cancer Res. 60, 970-975 (2000).
16. Shi W, Siemann DW. Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor. Br. J. Cancer 87, 119-126 (2002).
17. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. 2, 689-692 (1996).
18. Shi W, Teschendorf C, Muzyczka N, Siemann DW. Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Ther. 9, 513-521 (2002).
19. Denekamp J. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br. J. Radiol. 66, 181-196 (1993).
20. Baguley BC, Ching LM. DMXCAA: An antivascular agent with multiple host responses. Int. J. Radiat. Oncol. Biol. Phys. 54, 1503-1511 (2002).
21. Galbraith SM, Chaplin DJ, Lee F et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 21, 93-102 (2001).
22. Chaplin DJ, Pettit GR, Hill SA. Antivascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate. Anticancer Res. 19, 189-195 (1999).
23. Siemann DW, Warrington KH, Horsman MR. Targeting tumor blood vessels: An adjuvant strategy for radiation therapy. Radiother. Oncol. 57, 5-12 (2000).
24. Blakey DC, Westwood FR, Walker M et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin. Cancer Res. 8, 1974-1983 (2002).
25. Horsman MR, Murata R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int. J. Radiat. Oncol. Biol. Phys. (2003) (In Press).
26. Siemann DW, Mercer E, Lepler SE, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int. J. Cancer 99, 1-6 (2002).
27. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity Int. J. Radiat. Oncol. Biol. Phys. 5, 85-91 (1979).
28. DeVita VT, Hellman S, Rosenberg S. Cancer: Principles and Practice of Oncology. Lippincott-Raven, PA, USA (1997).
29. Siemann DW. Vascular targeting agents. Horizons Cancer Ther. 3, 4-15 (2002).
30. Murata R, Nishimura Y, Hiraoka M. An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 37, 1107-1113 (1997).
31. Lund EL, Bastholm L, Kristjansen PE. Therapeutic synergy of TNP-470 and ionizing radiation: Effects on tumor growth, vessel morphology and angiogenesis in human glioblastoma multiforme xenografts. Clin. Cancer Res. 6, 971-978 (2000).
32. Lee CG, Heijn M, di Tomaso E et al. Antivascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60, 5565-5570 (2000).
33. Griffin RJ, Lee SH, Rood KL et al. Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors. Neoplasia 2, 555-560 (2000).
34. Rofstad EK, Henriksen K, Galappathi S, Mathiesen B. Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dorminant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts. Cancer Res. 63, 4055-4061 (2003).
35. Gong H, Pottgen C, Stuben G, Havers W, Stuschke M, Schweigerer L. Arginine deiminase and other antiangiogenic agents inhibit unfavorable neuroblastoma growth: Potentiation by irradiation. Int. J. Cancer 106, 723-728 (2003).
36. Shi W, Teschendorf C, Muzyczka N, Siemann DW. Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiother. Oncol. 66, 1-9 (2003).
37. Teicher BA, Holden SA, Ara G et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents. Int. J. Cancer 57, 920-925 (1994).
38. Teicher BA, Holden SA, Dupuis NP et al. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res. Treat. 36, 227-236 (1995).
39. Gorski DH, Mauceri HJ, Salloum RM et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res. 58, 5686-5689 (1998).
40. Griscelli F, Li H, Cheong C et al. Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. Proc. Natl. Acad. Sci. USA 97, 6698-6703 (2000).
41. Geng L, Donnelly E, McMahon G et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 61, 2413-2419 (2001).
42. Hess C, Vuong V, Hegyi I et al. Effect of VEGF receptor inhibitor PTK787/ZK222584 [Correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br. J. Cancer 85, 2010-2016 (2001).
43. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61, 39-44 (2001).
44. Gupta VA, Jaskowiak NT, Beckett MA et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J. 8, 47-54 (2002).
45. Schueneman AJ, Himmelfarb E, Geng L et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 63, 4009-4016 (2003).
46. Mauceri HJ, Hanna NN, Beckett MA et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394, 287-291 (1998).
47. Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with anti-angiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin. Cancer Res. 9, 1957-1971 (2003).
48. Horsman MR, Overgaard J. The oxygen effect and the tumour microenvironment. In: Basic Clinical Radiobiolgy for Radiation Oncologists. Steel GG (Ed.), Edward Arnold, London, UK, 158-168 (2002).
49. Teicher BA, Holden SA, Ara G et al. Influence of an anti-angiogenic treatment on 9L gliosarcoma: Oxygenation and response to cytotoxic therapy. Int. J. Cancer 61, 732-737 (1995).
50. Leith JT, Papa G, Quaranto L, Michelson S. Modification of the volumetric growth responses and steady-state hypoxic fractions of xenografted DLD-2 human colon carcinomas by administration of basic fibroblast growth factor or suramin. Br. J. Cancer 66, 345-348 (1992).
51. Dark GG, Hill SA, Prise VE et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57, 1829-1834 (1997).
52. Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR. Enhancement of the antitumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br. J. Cancer 78, 439-445 (1998).
53. Li L, Rojiani A, Siemann DW. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 42, 899-903 (1998).
54. Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br. J. Cancer 81, 1318-1327 (1999).
55. Rojiani AM, Li L, Rise L, Siemann DW. Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of Aids-associated Kaposi's sarcoma. Acta Oncologica 41, 98-105 (2002).
56. Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int. J. Radiat. Oncol. Biol. Phys. 53, 164-171 (2002).
57. Siemann DW, Rojiani AM. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int. J. Radiat. Oncol. Biol. Phys. 54, 1512-1517 (2002).
58. Wilson WR, Li AE, Cowan DS, Siim BG. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int. J. Radiat. Oncol. Biol. Phys. 42, 905-908 (1998).
59. Nishiguchi I, Willingham V, Milas L. Tumor necrosis factor as an adjunct to fractionated radiotherapy in the treatment of murine tumors. Int. J. Radiat. Oncol. Biol. Phys. 18, 555-558 (1990).
60. Lew YS, Kolozsvary A, Brown SL, Kim JH. Synergistic interaction with arsenic trioxide and fractionated radiation in locally advanced murine tumor. Cancer Res. 62, 4202-4205 (2002).
61. Kimura K, Bowen C, Spiegel S, Gelmann EP. Tumor necrosis factor-α sensitizes prostate cancer cells to γ -irradiation-induced apoptosis. Cancer Res. 59, 1606-1614 (1999).
62. Murata R, Siemann DW, Overgaard J, Horsman MR. Interaction between combretastatin A4 disodium phosphate and radiation in murine tumours. Radiother. Oncol. 60, 155-161 (2001).
63. Landuyt W, Ahmed B, Nuyts S et al. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int. J. Radiat. Oncol. Biol. Phys. 49, 443-450 (2001).
64. Murata R, Siemann DW, Overgaard J, Horsman MR. Improved tumor response by combining radiation and the vascular damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat. Res. 156, 503-509 (2001).
65. Horsman MR, Murata R, Overgaard J. Combination studies with combretastatin and radiation: Effects in early and late responding normal tissues. Radiother. Oncol. 64, S50 (2002).
66. Sersa G, Willingham V, Milas L. Antitumor effects of tumor necrosis factor alone or combined with radiotherapy. Int. J. Cancer 42, 129-134 (1988).
67. 3). FEBS Lett. 519, 195-200 (2002).
68. Horsman MR, Murata R, Overgaard J. Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation. Acta Oncol. 40, 497-503 (2001).
69. Li L, Rojiani AM, Siemann DW. Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma. Acta Oncologica 41, 91-97 (2002).